Novel multidrug resistant microorganisms in critically ill: A potential threat

Minerva Anestesiologica

Volumn 81, Issue 1, 2015, Pages 52-64

  Grossi, P A ^a   Tebini, A ^a   Dalla Gasperina, D ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Anti infective agents; Critical illness; Drug resistance

Indexed keywords

AMIKACIN; AMPICILLIN; CEFTAROLINE; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; GENTAMICIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG MONITORING; ENTEROCOCCUS FAECALIS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEALTH CARE QUALITY; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MICROORGANISM; MULTIDRUG RESISTANT MICROORGANISM; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; BACTERIAL INFECTIONS; CROSS INFECTION; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFECTION CONTROL;

EID: 84925448056     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
2. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. Subtherapeutic initial β-lactam concentrations in selectcritically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012;142:30-9.
3. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. 'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 2012;25:626-33.
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9.
5. Peña C, Gómez-Zorrilla S, Oriol I, Tubau F, Dominguez MA, Pujol M et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis 2013;32:413-20.
6. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013;39:682-92.
7. Kouyos R, Klein E, Grenfell B. Hospital-Community interactions foster coexistence between methicillin-resistant strains of Staphylococcus aureus. PLoS Pathog 2013;9:e1003134.
8. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007) J Clin Microbiol 2008;46:2950-4.
9. Campanile F, Bongiorno D, Falcone M, Vailati F, Pasticci MB, Perez M et al. Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis. Eur J Clin Microbiol Infect Dis 2012;31:739-45.
10. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46:S3607.
11. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan VN et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high-vancomycin minimum inhibitory concentration. J Infect Dis 2011;204:340-7.
12. Christian JW, Chowdhury A, Patel VM, Shorr AF. Impact of vancomycin minimum inhibitory concentration on mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2012;33:1246-9.
13. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
14. Forstner C, Dungl C, Tobudic S, Mitteregger D, Lagler H, Burgmann H. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence. Clin Microbiol Infect 2013;19:E291-7.
15. Holmes NE, Johnson PD, Howden BP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol 2012;50:2548-52.
16. Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 2013;41:255-60.
17. An MM, Shen H, Zhang JD, Xu GT, Jiang YY. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infection: a metaanalysis of randomised controlled trials. Int J Antimicrob Agents 2013;41:426-33.
18. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54:621-9.
19. Alaniz C, Pogue JM. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial. Ann Pharmacother 2012;46:1432-5.
20. Sierra JM, Camoez M, Tubau F, Gasch O, Pujol M, Martin R et al. Low prevalence of Cfr-Mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy. PLoS One 2013;8: e59215.
21. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteremia. Drugs 2007;67:1483-512.
22. Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents 2011;37:202-9.
23. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285-92.
24. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical Breakpoint. Available on www.eucast.org
25. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agent Chemother 2010;54:5187-92.
26. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009;9:617-24.
27. Vidallac C, Steed ME, Rybak MJ. Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model. Antimicrob Agents Chemother 2011;55:2160-5.
28. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:2871-5.
29. Yang SJ. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin nonsusceptible strains of MRSA. Antimicrob Agents Chemother 2010;54:3161-9.
30. Dhard A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158-63.
31. Teed ME, Werth BJ, Ireland CE, Rybak MJ. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitropharmacokinetic/pharmacodynamics model of simulated endocardial vegetations. Antimicrob Agents Chemother 2012;56:5709-14.
32. Miro JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012;56:4511-5.
33. Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One 2012;7:e41870.
34. Werth B, Steed M, Kaatz GW, Rybak MJ. Evaluation of ceftaroline (CPT) activity against heteroresistant vancomycin intermediate Staphylococcus aureus (hVISA) and VISA methicillin-resistant S. aureus (MRSA) strains in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model: exploring the "Seesaw Effect". Antimicrob Agents Chemother 2013;57:2664-8.
35. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-4.
36. U.S. Food and Drug Administration: Tygacil (tigecycline): Label Change - Increased Mortality Risk. 27/09/2013.
37. European medicine Agency [Internet]. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/human/000644/WC500102228.pdf [cited 2013, Oct 15].
38. Agenzia Italiana del Farmaco [Internet]. Available at http://www.agenziafarmaco.gov.it/sites/default/files/nota-informativa-importante-1.pdf [cited 2013, Oct 15].
39. Campbell ML, Marchaim D, Pogue JM, Sunkara B, Bheemreddy S, Bathina P et al. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 2012;46:1587-97.
40. Fernandez-Guerrero ML, Herrero L, Bellver M, Gadea I, Roblas RF, de Górgolas M. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized patients with enterococcal bacteraemia. J Intern Med 2002;252:510-5.
41. st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med 2009;169:463-73.
42. Anderson DJ, Olaison L, Mcdonald JR, Miro JM, Hoen B, Selton-Suty C et al. Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from the international collaboration on endocarditis-merged database. Eur J Clin Microbiol Infect Dis 2005;24:665-70.
43. Arias CA. Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16:555-62.
44. European Antimicrobial Resistance Surveillance Network (EARS-Net) [Internet]. Available at http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC-DispForm.aspx?ID=998 [cited 2013, Jun 8].
45. Hayakawa K, Marchaim D, Vidaillac C, Lephart P, Pogue JM, Sunkara B et al. Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2011;32:52-5.
46. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains. Antimicrob Agents Chemother 2000;44:1062-6.
47. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010;65:1126-36.
48. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011;52:228-34.
49. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin resistant enterococci. J Antimicrob Chemother 2004;53:530-2.
50. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN et al. Ampicililn enhances daptomycin and cationic host defense peptide-mediated killing of ampicillin and vancomycin-resistant enterococcus faecium. Antimicrob Agents Chemother 2012;56:838-44.
51. Sierra-Hoffman M, Iznaola O, Goodwin M, Mohr J. Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother. 2012;56:6064.
52. nd European Conference on Clinical Microbiolgy and Infectious Diseases, London 31 march-3 april 2012. Clin Microbiol Infect 2012;18(S3):57.
53. thinternational symposium on modern concepts in endocarditis and cardiovascular infections, Dubrovnik 19-21 may 2013. Int J Antimicrob Agents 2013;41(S1):S26.
54. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012;56:3174-80.
55. Lauridsen TK, Bruun LE, Rasmussen RV, Arpi M, Risum N, Moser C et al. Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study. Eur J Clin Microbiol Infect Dis 2012;31:2567-74.
56. Ntokou E, Stathopoulos C, Kristo I, Dimitroulia E, Labrou M, Vasdeki A et al. Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2012;67:1819-23.
57. Gavaldà J, Len O, Miró JM, Muñoz P, Montejo M, Alarcón A et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007;146:574-9.
58. Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, de Alarcón A et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013;56:1261-8.
59. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae. Morb Mortal Wkly Rep 2013;62:165-70.
60. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention. Clin Infect Dis 2011;53:60-7.
61. Castanheira M, Sader HS, Jones RN. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist 2010;16:61-5.
62. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009;30:666-71.
63. Valentín-Martín A, Valverde-De Francisco A, Bosque-Vall M, Cantón-Moreno R. First report of colistin-resistant KPC-2 producing ST258-Klebsiella pneumoniae in Spain. Enferm Infecc Microbiol Clin. 2013;31:489-91.
64. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
65. Correa L, Martino MD, Siqueira I, Pasternak J, Gales AC, Silva CV et al. A hospital-based matched case - control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 2013;13:80.
66. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.
67. Zimmerman FS, Assous MV, Bdolah-Abram T, Lachish T, Yinnon AM, Wiener-Well Y. Duration of carriage of carbapenem-resistant Enterobacteriaceae following hospital discharge. Am J Infect Control 2013;41:190-4.
68. Antoniadou A, Kontopidou F, Poulaou G, Koratzanis E, Galani I, Papadomichelakis E et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007;59:786-90.
69. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB et al. In vitro activity of fosfomycin against blaKPC-1 containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010;54:526-9
70. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E et al. Hospital outbreak caused by Klebsiella pneumonia producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infec 2010;76:70-3.
71. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77.
72. Nilsson A, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003;47:2850-88.
73. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
74. Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates. Antimicrob Agents Chemother 2012;56:4856-61.
75. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatograpy. Antimicrob Agents Chemother 2003;47:1364-70.
76. Bergen PJ, Landersoderfer CB, Zhang J, Zhao M, Lee HJ, Nation RL et al. Pharmacokinetics and pharmacodynamics of "old" polymyxins: what is new? Diagnos Microbiol Infect 2012;74:213-23.
77. Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N et al. Pharmacokinetics of colistin methanesulphonate and colistin in critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005;49:4814-5.
78. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55:3022-24.
79. Gales AC, Jones Rn, sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011;66:2070-4.
80. Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE et al. Synergistic killing of ultidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011;55:5685-95.
81. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymixin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010;54:2732-4.
82. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 2009;53:2133-5.
83. Imberti R. Intravenous colistimethate administration and colistin lung tissue concentrations. Intensive Care Med 2010;36:1795; author reply 1796-7.
84. Silvestri L, de la Cal MA, van Saene HKF. Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth. Intensive Care Med 2012;38:1738-50.
85. Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 2012;33:14-19.
86. Vincent JL, Jacobs F. Effect of selective decontamination on antibiotic resistance. Lancet Infect Dis 2011;11:337-8.
87. de Smet AMGA, Kluytmans JAJW, Blok HEM, Mascini EM, Benus RFJB, Bernards AT et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011;11:372-80.
88. Bion J, Taylor N, Petros AJ, Silvestri L, van Saene HKF. Selective digestive decontamination and antibiotic resistance. Lancet Infect Dis 2012;12:181
89. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH, on behalf of the SuDDICU Canadian Study Group. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Disease 2013;13:328-41
90. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012;18:439-48.
91. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-50.
92. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55:3002-4.
93. Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013;57:2900-1.
94. Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013;57:2388-90.
95. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012;39:86-9.
96. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013;68:1183-92.
97. Vazquez JA, González Patzán LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012;28:1921-31.
98. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR et al. Ceftazidime-Avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 2013;73:159-77.
99. Goossens H Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units results from the European MYSTIC study group. Clin Microbiol Infect 2003;9:980-3.
100. Lister PD, Daniel J, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582-610.
101. Clinical and Laboratory Standards Institute. Summary mutes: Subcommittee on Antimicrobial Susceptibility Testing.
102. Juan C, Conejo MC, Tormo N, Gimeno C, Pascual Á, Oliver A. Challenges for accurate susceptibility testing, detection and interpretation of β-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study. J Antimicrob Chemother 2013;68:619-30.
103. Yamagishi Y, Terada M, Ohki E, Miura Y, Umemura T, Mikamo H. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa. J Infect Chemother 2012;18:127-9.
104. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 2011;11:381-93.
105. Pollini S, Maradei S, Pecile P, Olivo G, Luzzaro F, Docquier JD et al. FIM-1, a new acquired metallo-β-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob Agents Chemother 2013;57:410-6.
106. Valdes JM, Baitch AL, Smith RP, Hammer M, Ritz W. The effect of rifampicin on the in vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa. J AntimicrobChemother 1990;25:575-84.
107. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006;10:R48.
108. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012;39:105-14.
109. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010;35:219-26.
110. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44.
111. Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 2010;65:1589-93.
112. Arroyo LA, Mateos I, Gonzalez V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009;53:1295-6.
113. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009;15:980-2.
114. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007;60:1163-7.
115. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies J Antimicrob. Chemother 2012;67:1607-15.
116. Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii including colistin- or tigecycline-resistant isolates. J Med Microbiol 2012;61:353-60.